Dr. Gordon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Biesterfield Rd.
Cancer Institute Bld. #5, Ste. 210
Elk Grove Village, IL 60007Phone+1 847-437-3312Fax+1 847-981-5917
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1983 - 1986
- Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
- Johns Hopkins University School of MedicineClass of 1977
Certifications & Licensure
- IL State Medical License 1994 - 2026
- MD State Medical License 1983 - 2022
- FL State Medical License 2000 - 2005
- CT State Medical License 1995 - 1997
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer Start of enrollment: 2001 Jun 01
Publications & Presentations
PubMed
- 788 citationsBody mass index, serum sex hormones, and breast cancer risk in postmenopausal women.Timothy J. Key, Paul N. Appleby, Gillian K Reeves, Andrew W. Roddam, Joanne F. Dorgan
Journal of the National Cancer Institute. 2003-08-20 - 93 citationsRelationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancerGary B. Gordon, Trudy L. Bush, Kathy J. Helzlsouer, Susan R. Miller, George W. Comstock
Cancer Research. 1990-07-01 - 568 citationsVenetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F. Seymour
The Lancet. Oncology. 2016-06-01
Press Mentions
- ODAC Recommends Approval of Epoetin Alfa BiosimilarMay 25th, 2017
- Veliparib Falls Short in Phase III NSCLC, TNBC TrialsApril 20th, 2017
- The 20-Year Journey Yielding a New Weapon Against CancerJanuary 10th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: